A proposed path to explaining the unexplained anemia of aging
- PMID: 41206919
- PMCID: PMC12758967
- DOI: 10.1093/gerona/glaf251
A proposed path to explaining the unexplained anemia of aging
Abstract
Approximately 17% of people aged 65 years and older are anemic, and 10% of death certificates report anemia as a secondary cause of death in the United States. Nonetheless, anemia remains unexplained in 30%-50% of older adults. This unexplained anemia of aging (UAA) is a diagnosis of exclusion. The mechanism, impact, and progression of UAA remain unknown. At older ages, anemia adds to pre-existing co-morbidities with significant adverse health consequences, representing a compelling unmet clinical concern. The National Institute on Aging held a workshop in 2024 to discuss current knowledge and research opportunities. Topics included the epidemiology of anemia at older age and its clinical implications; probable mechanism(s) underlying UAA, that is, low-grade inflammation's effects on erythropoiesis; the role of microbiota in iron regulation in bone marrow; the importance of ruling out a diagnosis of leukemic clonal hematopoiesis (CH), which is more prevalent in older age; the role of senescence and aging governing hematopoiesis; and the effects of sex hormones on hematopoietic stem cell aging. Understanding the roles of these factors could reduce the proportion of the older anemic population whose anemia remains unexplained and offer insights into new potential diagnostic and intervention strategies. Speakers reviewed previous clinical trials in patients with UAA and CH. They discussed lessons learned and future research priorities, including efforts to develop new diagnostic algorithms and potential uses of machine learning.
Keywords: Clonal hematopoiesis; Inflammaging; Senescence.
© The Author(s) 2025. Published by Oxford University Press on behalf of the Gerontological Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
A.E.D. participated in advisory boards and/or had a consultancy with and received honoraria from Bristol Meyers Squibb, Agios, and Novartis. A.E.D. served on clinical trial committees or DSMB for Novartis, Agios, Abbvie, Kura, Geron, Servier, Keros, Shuattuck labs, and Bristol Meyers Squibb. A.A. participated to Advisory for Astra Zeneca and Consultancy for Daiichi Sankyo. T.G. participated in advisory boards, and/or had a consultancy with and received honoraria from, and/or owns equity in Intrinsic LifeSciences, City Therapeutics, Chugai, Ionis, Pharmacosmos, Dexcel, Silence, RallyBio, and Disc Medicine. T.A.K. had a consultancy with and received research funding from Agios Pharmaceuticals and Novo Nordisc. K.E.W. has an Ownership in FGF Therapeutics, Inc., and funding from Calico Labs. The remaining authors declare no competing financial interests. IB serves on the editorial board of the Biological Sciences section of the
References
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
